H-bTMB

CI-VAR-00001865Explore in graph →CIViC 5360

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
TMB H-bTMB	Immune Checkpoint Inhibitor	Predictive	B	Supports Sensitivity Response	4	accepted	EID12724 The use of circulating tumor DNA in blood for TMB assessment was tested. The cancer gene panel NCC-GP150, which covers the whole exon regions of 150 genes, was created and tested for correlation again… (full text at CIViC) PMID 30816954 · Wang et al., 2019 · Open in CIViC	civic
Nonsquamous Non-small Cell Lung Cancer1unmapped disease
TMB H-bTMB	Atezolizumab	Predictive	B	Supports Sensitivity Response	2	submitted	EID12977 In the BFAST (NCT03178552) trial for targeted or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer, Cohort C evaluated TMB as a biomarker o…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.